ArticleAnnals of medicine and surgery (2012)2026
Taletrectinib as an emerging therapy for ROS1-positive non-small cell lung cancer: findings from TRUST phase 2 trials.
Hassan Khalid et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.